Induction of inflammatory bowel disease flares by golimumab: report of three patients with enteropathic spondylarthritis or ankylosing spondylitis and comorbid colitis.

摘要

Golimumab is a fully human monoclonal antibody against tumor necrosis factor alpha (TNFalpha) and is approved for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS) (1). In contrast to the anti-TNF antibodies infliximab and adalimumab, which are also approved for Crohn's disease (CD), no data about the efficacy of golimumab in treating inflammatory bowel disease (IBD) are available. We present the cases of 2 patients with CD-associated spondylarthritis and 1 patient with AS and comorbid colitis who were treated with adalimumab for their rheumatic disease, and who experienced marked flares in their IBD after therapy was changed to golimumab.